These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35378214)

  • 1. Critical clinical gaps in cancer precision nanomedicine development.
    Gan WW; Chan LW; Li W; Wong TW
    J Control Release; 2022 May; 345():811-818. PubMed ID: 35378214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology as a Delivery Tool for Precision Cancer Therapies.
    Sharma B; Crist RM; Adiseshaiah PP
    AAPS J; 2017 Nov; 19(6):1632-1642. PubMed ID: 29019032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review on immuno-nanomedicine for breast cancer therapy: Technical challenges and troubleshooting measures.
    Saravanakumar K; Anbazhagan S; Pujani Usliyanage J; Vishven Naveen K; Wijesinghe U; Xiaowen H; Vishnu Priya V; Thiripuranathar G; Wang MH
    Int Immunopharmacol; 2022 Feb; 103():108433. PubMed ID: 34922248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-Installed Nanocarriers toward Precision Therapy.
    Mi P; Cabral H; Kataoka K
    Adv Mater; 2020 Apr; 32(13):e1902604. PubMed ID: 31353770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active targeting strategy in nanomedicines using anti-EGFR ligands - A promising approach for cancer therapy and diagnosis.
    Nguyen PV; Hervé-Aubert K; Chourpa I; Allard-Vannier E
    Int J Pharm; 2021 Nov; 609():121134. PubMed ID: 34571073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heteromultivalent ligand-decoration for actively targeted nanomedicine.
    Modery-Pawlowski CL; Gupta AS
    Biomaterials; 2014 Mar; 35(9):2568-79. PubMed ID: 24411677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omics-based nanomedicine: the future of personalized oncology.
    Rosenblum D; Peer D
    Cancer Lett; 2014 Sep; 352(1):126-36. PubMed ID: 23941830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting.
    Fu X; Shi Y; Qi T; Qiu S; Huang Y; Zhao X; Sun Q; Lin G
    Signal Transduct Target Ther; 2020 Nov; 5(1):262. PubMed ID: 33154350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetics advancing personalized nanomedicine in cancer therapy.
    Liu S
    Adv Drug Deliv Rev; 2012 Oct; 64(13):1532-43. PubMed ID: 22921595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.
    Zhang XQ; Xu X; Bertrand N; Pridgen E; Swami A; Farokhzad OC
    Adv Drug Deliv Rev; 2012 Oct; 64(13):1363-84. PubMed ID: 22917779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-mediated nanomedicines against breast cancer: a review.
    Picheth GF; Ganzella FAO; Filizzola JO; Canquerino YK; Cardoso GC; Collini MB; Colauto LB; Figueroa-Magalhães MC; Cavalieri EA; Klassen G
    Nanomedicine (Lond); 2022 Apr; 17(9):645-664. PubMed ID: 35438008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the development of nanoparticle-based imaging agents: Characterization and biology.
    Crist RM; Dasa SSK; Liu CH; Clogston JD; Dobrovolskaia MA; Stern ST
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1665. PubMed ID: 32830448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlocking the potential of nanomedicine: advances in precision targeting strategies.
    Celia C; Teesalu T; Santos HA
    Drug Deliv Transl Res; 2024 Oct; 14(10):2593-2597. PubMed ID: 39095582
    [No Abstract]   [Full Text] [Related]  

  • 15. Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation.
    Gonzalez-Valdivieso J; Girotti A; Schneider J; Arias FJ
    Int J Pharm; 2021 Apr; 599():120438. PubMed ID: 33662472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized nanomedicine: future medicine for cancer treatment.
    Shiekh FA
    Int J Nanomedicine; 2013; 8():201-2. PubMed ID: 23326194
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted nanotheranostics for personalized cancer therapy.
    Diou O; Tsapis N; Fattal E
    Expert Opin Drug Deliv; 2012 Dec; 9(12):1475-87. PubMed ID: 23092183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
    Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
    Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalizing Biomaterials for Precision Nanomedicine Considering the Local Tissue Microenvironment.
    Oliva N; Unterman S; Zhang Y; Conde J; Song HS; Artzi N
    Adv Healthc Mater; 2015 Aug; 4(11):1584-99. PubMed ID: 25963621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine-based strategies to target and modulate the tumor microenvironment.
    Mendes BB; Sousa DP; Conniot J; Conde J
    Trends Cancer; 2021 Sep; 7(9):847-862. PubMed ID: 34090865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.